Company overview
Basic information
Company name
Laverta, UAB
Company code
300071826
VAT code
LT100001358918
Registered address
Šiauliai, Metalistų g. 6B, LT-78107
Registration date
2004-12-06
Company age: 21 y. 10 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://www.laverta.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Renting and leasing of trucks
Ownership form
Private without foreign capital
UAB "Laverta"
Company code: 300071826
Address: Šiauliai, Metalistų g. 6B, LT-78107
VAT code: LT100001358918
Description
This description was generated by artificial intelligence.
Laverta, UAB (company code 300071826) is an operational private limited liability company registered in 2004. It operates as a private entity in the national private non-financial companies sector and is managed by a CEO only. The company is privately owned, with more than 50% of share capital held by Lithuanian natural and legal persons and no foreign investor capital. Its registered address is Šiauliai, Metalistu g. 6B, LT-78107, in Šiauliu m. sav., Šiauliu apskr. The company’s activity is classified under EVRK O.77.12.10, Rental of heavy goods vehicles. In 2025, Laverta generated revenue of €1.34M and net profit of €645.1K, with a profit margin of 48.3%. Revenue decreased by 12.1% year on year and by 19.1% over two years, while net profit remained positive but below the 2024 level of €1.48M. At the end of 2025, equity stood at €13.04M, total assets at €17.62M and liabilities at €4.58M, with an equity ratio of 74.0%. The company employed 1 person on average in 2025 and 1 person so far in 2026.
Download a detailed company report
Make confident decisions with all the information about Laverta, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.